

TEXAS STATE BOARD OF PHARMACY

Held via Videoconference Tuesday, May 5, 2020

MINUTES¹

BOARD BUSINESS MEETING

Tuesday, May 5, 2020

President Julie Spier, R.Ph., called the meeting to order at 9:01 a.m. via videoconference in accordance with the Office of the Texas Governor's suspension of applicable sections of Chapter 551 of the Tex. Gov't Code, effective March 16, 2020, in response to the disaster declaration issued March 13, 2020, for the State of Texas. Other Board Members present via videoconference were Vice President Donnie Lewis, R.Ph.; Treasurer Jenny Downing Yoakum, R.Ph.; Rick Fernandez, R.Ph.; Daniel Guerrero; Lori Henke, Pharm.D.; Bradley A. Miller, Ph.T.R.; Donna Montemayor, R.Ph.; Chip Thornsburg; Suzette Tijerina, R.Ph.; and Rick Tisch.

Staff present via videoconference were Allison Vordenbaumen Benz, R.Ph., M.S., Executive Director/Secretary; Kerstin Arnold, General Counsel; Megan Holloway, Deputy General Counsel; Caroline Hotchkiss, Director of Enforcement; Ann Driscoll, Ph.T.R., Team Manager; Lily Moreno, Executive Assistant; and Shayda Bakhshi, Outreach Coordinator.

A. Announcements

 Ms. Benz made general announcements and reviewed the meeting procedures.

B. <u>Discussion and Approval of Minutes of Previous Meetings</u> (Item B)

Following discussion, the motion was made by Ms. Henke to approve the minutes of the Board Business Meeting held February 4, 2020; the minutes of the

¹See agenda and corresponding attachments for supporting materials.

Emergency Board Business Meeting held March 20, 2020; and the minutes of the Executive Committee Meeting held April 20, 2020. The motion was seconded by Mr. Miller and passed unanimously.

C. <u>Discussion of and Possible Action Regarding Rules</u>

Final Adoption of Rules

 Rule Concerning Temporary Suspension or Restriction Procedures (§281.35) (Item C.1.1)

Ms. Holloway explained that the Board voted to propose new rule §281.35 during its February 4, 2020 meeting. The proposed rule was published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to §281.35 and explained that the new rule details procedures for the temporary suspension or restriction of a license or registration.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by Board Order, new rule §281.35, as presented. The motion was seconded by Ms. Henke and passed unanimously.

 Rules Concerning Elimination of Pharmacist Intern-Trainee Designation (§§283.2, 283.4, 283.5, and 283.6) (Items C.1.2.1, C.1.2.2, C.1.2.3, and C.1.2.4)

Ms. Holloway explained that the Board voted to propose the amendments to §§283.2, 283.4, 283.5, and 283.6 during its February 4, 2020 meeting. The proposed amendments were published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to the amendments to §\$283.2, 283.4, 283.5, and 283.6. Ms. Holloway explained that the amendments to §283.2 remove the definition of and references to a pharmacist intern-trainee; the amendments to §283.4 remove references to a pharmacist intern-trainee and certain requirements for a pharmacist intern, and correct grammatical errors; the amendments to §283.5 remove references to a pharmacist intern-trainee; and the amendments to §283.6 remove references to a pharmacist intern-trainee, clarify that a pharmacist preceptor must be certified by the board, and remove a fee for a duplicate or amended certificate.

Following discussion and review of the Preambles and Orders Adopting Rules, the motion was made by Mr. Lewis to approve for adoption, by Board Order, amendments to §§283.2, 283.4, 283.5, and 283.6, as

presented. The motion was seconded by Mr. Tisch and passed unanimously.

 Rules Concerning Fee for Change of Name (§§295.1 and 297.9) (Items C.1.3.1 and C.1.3.2)

Ms. Holloway explained that the Board voted to propose the amendments to §§295.1 and 297.9 during its February 4, 2020 meeting. The proposed amendments were published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to the amendments to §§295.1 and 297.9. She explained that to reflect the new procedure of no longer charging these fees, the amendments to §295.1 remove the change of name fee for pharmacists and the amendments to §297.9 remove the change of name fee for pharmacy technicians and pharmacy technician trainees.

Following discussion and review of the Preambles and Orders Adopting Rules, the motion was made by Mr. Thornsburg to approve for adoption, by Board Order, amendments to §§295.1 and 297.9, as presented. The motion was seconded by Mr. Guerrero and passed unanimously.

 Rules Concerning Administrative Actions as a Result of a Compliance Inspection (§291.19) (Item C.1.4)

Ms. Holloway explained that the Board voted to propose the amendments to §291.19 during its February 4, 2020 meeting. The proposed amendments were published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to the amendments to §291.19 and explained that the amendments update the actions that may be taken after violations are observed during a compliance inspection to reflect current procedures.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Fernandez to approve for adoption, by Board Order, amendments to §291.19, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

 Rules Concerning Drug or Device Labeling in a Clinic Pharmacy (§291.93) (Item C.1.5)

Ms. Holloway explained that the Board voted to propose the amendments to §291.93 during its February 4, 2020 meeting. The proposed amendments were published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway explained that Board staff recommended that the proposed amendments to §291.93 be withdrawn because staff had identified a problem with the amendments, in that the new label the proposed amendments provide for does not contain all the required elements of a label.

Following discussion, the motion was made by Mr. Guerrero to withdraw the proposed amendments to §291.93. The motion was seconded by Mr. Tisch and passed unanimously.

 Rules Concerning Limited Prescription Delivery Pharmacy (Class H) (§291.155) (Item C.1.6)

Ms. Holloway explained that the Board voted to propose the repeal of §291.155 during its February 4, 2020 meeting. The proposed repeal was published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to the repeal of §291.155 and explained that the repeal removes rules for a class of pharmacy that no longer exists.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Fernandez to approve for adoption, by Board Order, the repeal of §291.155, as presented. The motion was seconded by Mr. Guerrero and passed unanimously.

 Rules Concerning Mental Health Awareness Continuing Education (§295.8) (Item C.1.7)

Ms. Holloway explained that the Board voted to propose the amendments to §295.8 during its February 4, 2020 meeting. The proposed amendments were published in the April 3, 2020 issue of the *Texas Register*, and no comments were received.

Ms. Holloway directed the Board's attention to the amendments to §295.8 and explained that the amendments add a requirement for mental health awareness continuing education and clarify the continuing education requirements for pharmacists during their initial licensure period.

Following discussion and review of the Preamble and Order Adopting Rules, the motion was made by Mr. Tisch to approve for adoption, by Board Order, amendments to §295.8, as presented. The motion was seconded by Mr. Miller and passed unanimously.

Proposal of Rules

 Rules Concerning Penalty for Failure to Access Prescription Monitoring Program (§281.65) (Item C.2.1)

Ms. Holloway directed the Board's attention to suggested amendments to rule language concerning the assessment of a penalty against a pharmacist for failure to access the Prescription Monitoring Program. She explained the proposed amendments to §281.65 add an administrative penalty for failing to access the Prescription Monitoring Program for a patient's information before dispensing opioids, benzodiazepines, barbiturates, or carisoprodol, and update a citation reference.

Following discussion, the motion was made by Mr. Thornsburg to approve for proposal amendments to §281.65, as presented. The motion was seconded by Mr. Lewis and passed unanimously.

Rules Concerning Prescription Pick-Up Locations (§291.9) (Item C.2.2)

Ms. Holloway directed the Board's attention to suggested amendments to rule language concerning prescription pick-up locations and explained the proposed amendments to §291.9 remove an outdated reference to Class H pharmacies, which no longer exist due to the Board's repeal of §291.155.

Following discussion, the motion was made by Mr. Lewis to approve for proposal amendments to §291.9, as presented. The motion was seconded by Mr. Guerrero and passed unanimously.

 Rules Concerning Requirements for Using an Automated Pharmacy System (§291.121) (Item C.2.3)

Ms. Holloway directed the Board's attention to suggested amendments to rule language concerning remote pharmacy services using automated pharmacy systems. She explained the proposed amendments to §291.121 allow remote pharmacy services to be provided using an automated pharmacy system at healthcare facilities regulated under Chapter 241 of the Texas Health & Safety Code Ann., and remove the limitation that the services may only be provided to inpatients of the remote site.

Following discussion, the motion was made by Mr. Tisch to approve for proposal amendments to §291.121, as presented. The motion was seconded by Mr. Miller and passed unanimously.

Rules Concerning Requirement for Sink (§291.153) (Item C.2.4)

Ms. Holloway directed the Board's attention to suggested amendments to rule language concerning the requirement for a sink in a Class G

Pharmacy. She explained the proposed amendments to §291.153 clarify that a sink exclusive of restroom facilities is not required for a Class G pharmacy and correct grammatical errors.

Following discussion, the motion was made by Ms. Montemayor to approve for proposal amendments to §291.153, as presented. The motion was seconded by Mr. Fernandez and passed unanimously.

Rule Review

For Proposal

Ms. Holloway directed the Board's attention to the Board Rule Review Plan for FY 2018-2021 (Item C.3)

- Chapter 291 Concerning Pharmacies (Institutional Pharmacy (Class C)) (§§291.71 – 291.77) (Item C.3.1.1)
- Chapter 303 Concerning Destruction of Dangerous Drugs & Controlled Substances (§§303.1 – 303.3) (Item C.3.1.2)

Following discussion, in accordance with Government Code §2001.039, the motion was made by Ms. Tijerina to approve for proposal as presented, the review of Chapter 291 (§§291.71 – 291.77) and Chapter 303 (§§303.1 – 303.3). The motion was seconded by Mr. Fernandez and passed unanimously.

D. <u>Discussion of and Possible Action Concerning Reports of Committees/</u> Task Forces

 Report on Pilot Project Concerning Automated Dispensing and Delivery Systems (Item D.1)

The Board reviewed a report from Sam's Club and MedAvail regarding the pilot project concerning Automated Dispensing and Delivery Systems.

Report on Compounding Advisory Group (Item D.2)

Ms. Benz directed the Board's attention to the list of members for the Compounding Advisory Group. Ms. Benz explained that the first Compounding Advisory Group meeting that had been scheduled for late March was postponed and would be rescheduled, possibly as a virtual meeting, for late summer or early fall.

Report on PMP Advisory Committee (Item D.3)

Ms. Benz explained that the Prescription Monitoring Program (PMP) Advisory Committee meeting scheduled for April was not held, and the

next meeting scheduled for July would most likely be a virtual meeting. Ms. Benz directed the Board's attention to a survey conducted by Board staff and submitted to the PMP Advisory Committee members. She explained that the survey results indicated that the committee members would like the Board to continue to seek funding for statewide integration, NarxCare, and Clinical Alerts from the Texas Legislature.

E. <u>Discussion of and Possible Action Concerning the Following Reports and Discussions</u>

- Financial Report
 - Review of FY2019 Expenditures (Item E.1.1)
 - Ms. Benz reviewed the expenditures for the second quarter of FY2020 (December 1, 2019 February 29, 2020) for the Board.
 - Review of Board Member Travel Budget (Item E.1.2)
 - Ms. Benz reviewed the Board Member Travel Budget for the second quarter of FY2020 (December 1, 2019 February 29, 2020).
 - Consideration of Material Changes to Contracts for Goods and Services Awarded Under Chapter 2155 of Texas Government Code (Item E.1.3)
 - Ms. Benz reported that there were no material changes to contracts for goods and services.
 - Review and Approval of Legislative Appropriations Request for FY2022-2023 (Item E.1.4)

Ms. Benz directed the Board's attention to the Proposed Exceptional Items for the FY22-23 Legislative Appropriations Request. Ms. Benz reviewed the proposed exceptional items, including several items associated with the Board office move planned for Summer 2022 and items associated with statewide integration for the Prescription Monitoring Program. Ms. Benz explained that these items were reviewed and approved by the Executive Committee in April to be presented to the full Board. Ms. Benz also reviewed examples of potential licensee fee changes needed to cover the increases if funding for the proposed exceptional items is appropriated.

Following review and discussion, the motion was made by Mr. Guerrero to approve the Proposed Exceptional Items for FY2022-2023 for the Legislative Appropriations Request, as

presented, and allowing for Ms. Benz in consultation with the board president to make adjustments for any additional circumstances that might arise. The motion was seconded by Mr. Fernandez and passed unanimously.

- Professional Recovery Network
 - Ms. Hotchkiss discussed performance measures regarding the number of individuals participating in the peer assistance program for the second quarter of FY2020 (December 1, 2019 – February 29, 2020). (Item E.2.1)
 - President Spier recognized Eden Males, Program Director,
 Professional Recovery Network (PRN). Ms. Males directed the
 Board's attention to the PRN expense report through the second quarter of FY2020 (December 1, 2019 February 29, 2019).
 Ms. Males reviewed PRN activities for the Board. (Item E.2.2)

President Spier recessed the meeting at 9:55 a.m.

President Spier reconvened the meeting at 10:05 a.m.

• Review and Approval of *FY2021-2025 Strategic Plan* and Report on Customer Service Survey (Items E.3 and E.4)

Ms. Benz directed the Board's attention to a draft of the *FY2021-2025* Strategic Plan and to the Customer Service Survey, located at the end of the Strategic Plan.

Following review, the motion was made by Mr. Lewis to approve the *FY2021-2025 Strategic Plan*, as presented. The motion was seconded by Mr. Miller and passed unanimously.

Review and Approval of FY2021 Calendar of Events (Item E.5)

Ms. Benz directed the Board's attention to a draft of the FY2021 Calendar of Events.

Following review, the motion was made by Mr. Lewis to approve the *FY2021 Calendar of Events*. The motion was seconded by Ms. Tijerina and passed unanimously.

 Discussion Concerning National Association of Boards of Pharmacy Proposed Resolutions (Item E.6)

Ms. Benz reported that the National Association of Boards of Pharmacy (NABP) Annual Meeting would be held virtually on May 14, 2020, for delegates to attend. Ms. Benz reviewed the proposed resolutions that would be voted on at the Annual Meeting.

Report on the Prescription Monitoring Program (Item E.7)

Ms. Benz presented a report on the Prescription Monitoring Program regarding data for the second quarter of FY2020 (December 1, 2019 – February 29, 2020).

 Report on Appeals from State Office of Administrative Hearing Cases and Other Court Actions (Item E.8)

Ms. Arnold provided an update concerning a petition filed in district court in Travis County that seeks to invalidate the restriction that licensed Texas physicians cannot dispense prescriptions to patients at their offices without a pharmacy license. Ms. Arnold advised the Board that staff is continuing to work with the Texas Attorney General's Office, and that if a trial is held, it likely would be set in late summer or early fall.

Ms. Arnold also provided information on an appeal that was filed by a pharmacist following a default disciplinary order. Ms. Arnold reported that the case was moving to trial.

 Report on Agency Activities in Response to COVID-19 (Coronavirus) (Item E.9)

Ms. Benz provided a report regarding actions and activities taken by Board staff in response to the COVID-19 pandemic. Ms. Benz reviewed rule waivers submitted by Board staff and approved by the Governor.

In response to a question from Ms. Montemayor concerning the status of COVID-19 testing, Ms. Benz explained that based on conversations with staff of the Office of the Texas Governor and the Texas Medical Board, pharmacists can perform CLIA-waived testing, but cannot order testing which involves screening to determine who or who should not receive a test unless ordered under a standing protocol from a physician.

 Discussion of Possible Statutory Changes for Consideration During the 87th Session of the Texas Legislature (Item E.10)

Ms. Benz explained that Board members can suggest any statutory changes relating to the Board's operation. No suggestions were made.

 Update on Legislation Passed During the 86th Texas Legislative Session that have an Impact on TSBP and/or the Practice of Pharmacy. (Item E.11)

Ms. Benz directed the Board's attention to an updated action chart concerning legislation that was passed during the 86th Texas Legislative Session that has an impact on the Board and/or the practice of pharmacy. The chart contains the bill numbers and the Board's progress in

implementation of the bill. She reported that the most recent adoption of rules at the current meeting should complete the outstanding items on the action chart.

 Review and Accreditation Council for Pharmacy Education Evaluation of Accredited Status for Texas Southern University College of Pharmacy and Health Sciences and Texas Tech University Health Sciences Center School of Pharmacy (Item E.12)

Ms. Henke reported on her participation with the Accreditation Council for Pharmacy Education (ACPE) Evaluation of Accredited Status for Texas Tech University Health Sciences Center School of Pharmacy, with attention and appreciation given to the level of scrutiny by ACPE in surveying the programs.

President Spier reported that her experience with the ACPE Evaluation of Accredited Status for Texas Southern University College of Pharmacy was similar and encouraged other Board members to participate if given the opportunity.

F. Consideration of and Possible Action Concerning Enforcement Reports

 Report on Complaints Closed and Dismissed During the Previous Quarter (Item F.1)

Ms. Hotchkiss reported on complaints dismissed and closed during the second quarter of FY2020 (December 1, 2019 – February 29, 2020). The report also included quarterly averages for FY2020 as compared to FY2019, as well as percentage change from FY2019 to FY2020.

Report on Status of Active/Pending Complaints (Item F.2)

The Board received the Report on Status of Active/Pending Complaints.

Ms. Hotchkiss reviewed the report for the Board.

G. Consideration of and Possible Action Concerning Disciplinary Orders

- Report on Agreed Board Orders Entered by Executive Director (Item G.1)
 - The Board reviewed 18 Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from February 18, 2020, through May 4, 2020.
 - The Board reviewed 20 Agreed Board Orders concerning pharmacies and pharmacists that had been entered by the

Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from February 18, 2020, through May 4, 2020.

- The Board reviewed 2 Confidential Agreed Board Orders concerning pharmacists that had been entered by the Executive Director on behalf of the Board, in accordance with the Board's directives, during the period from March 17, 2020, through April 15, 2020.
- Discussion of and Action on Proposed Agreed Board Orders and Proposed Default Board Orders, Executive Session to Consider Discussion of and Action on Disciplinary Orders and Discussion of and Action on Proposed Remedial Plans (Items G.2, G.3, and G.4)

The Board reviewed the alleged violations, as well as the recommended sanctions for each of the following:

- 11 proposed Agreed Board Orders concerning pharmacy technicians and pharmacy technician trainees who appeared for an Informal Conference;
- 7 proposed Default Board Orders concerning pharmacy technicians and pharmacy technician trainees who did not appear for an Informal Conference;
- 15 proposed Agreed Board Orders concerning pharmacies and pharmacists (Alternative Resolutions);
- 12 proposed Agreed Board Orders concerning pharmacies and pharmacists who appeared for an Informal Conference;
- 5 proposed Confidential Agreed Board Orders concerning pharmacists who appeared for an Informal Conference.
- 2 proposed Remedial Plans concerning pharmacists (Alternative Resolutions); and
- 3 proposed Remedial Plans concerning pharmacists following an Informal Conference.

The motion was made by Ms. Henke to approve the proposed Disciplinary Orders and Remedial Plans, as presented. The motion was seconded by Mr. Guerrero and passed as follows:

No.	Name	T, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
1	Calanjanae Baker	Т	ABO	2019-04337	8-0-2	Yoakum, Miller
2	Stephanie Hunt	Т	ABO	2018-06066	8-0-2	Yoakum, Miller
3	Ardynea Oladekojo	Т	ABO	2019-02532	8-0-2	Yoakum, Miller
4	Jasmine Smalley	Т	ABO	2020-00461	8-0-2	Yoakum, Miller
5	Shakira Smith	Т	ABO	2019-03601	8-0-2	Yoakum, Miller
6	Rochelle Maria King	Т	ABO	2020-00835	8-0-2	Henke, Guerrero
7	Phillip Ernest Meili	Т	ABO	2020-01501	8-0-2	Henke, Guerrero
8	Rachel Brantley	Т	ABO	2020-01359	9-0-1	Lewis
9	Mayra Fabela	Т	ABO	2019-04163	9-0-1	Lewis
10	Keshandra Shundrah Wilson	Т	ABO	2020-02266	9-0-1	Lewis
11	Thomas E. Moreno Chitty	Т	ABO	2019-04577	10-0-0	-
12	Tyjon Altorian Shivers	Т	DBO	2019-02578	8-0-2	Yoakum, Miller
13	Suzanne Marie Vaughn	Т	DBO	2020-00746	8-0-2	Yoakum, Miller
14	Sidney Munger	Т	DBO	2019-02744	8-0-2	Henke, Guerrero
15	Amy Elizabeth Ross	Т	DBO	2020-00739	8-0-2	Henke, Guerrero
16	Raveen Ann Marie Shepherd	Т	DBO	2019-02235	8-0-2	Henke, Guerrero
17	Kierstin Strawn	Т	DBO	2019-04983	8-0-2	Henke, Guerrero
18	Benjamin Cowart	Т	DBO	2019-01862	9-0-1	Lewis
19	CVS/pharmacy #6800	Р	ABO	2019-01492	9-0-1	Tijerina
20	CVS/pharmacy #10402	Р	ABO	2019-03010	9-0-1	Tijerina
21	Achille Leonard Njonkou	R	ABO	2020-00172	9-0-1	Tijerina
22	Family Pharmacy Care	Р	ABO	2020-00311	10-0-0	-
23	Audrey Au Lam	R	ABO	2020-00315	10-0-0	-
24	H.E.B. Pharmacy #071	Р	ABO	2020-00515	9-0-1	Montemayor
25	Kroger Pharmacy #544	Р	ABO	2018-06343	10-0-0	-
26	Morgan Lee	R	ABO	2019-05551	10-0-0	-
27	Nextcare Pharmacy	Р	ABO	2020-01141	10-0-0	-
28	SEM Pharmacy & Medical Supply LLC	Р	ABO	2019-05594	10-0-0	-
29	Walgreens	Р	ABO	2020-00101	9-0-1	Fernandez
30	Walgreens #03342	Р	ABO	2020-00340	9-0-1	Fernandez
31	Walgreens #09104	Р	ABO	2019-04811	9-0-1	Fernandez
32	Walgreens #5733	Р	ABO	2019-06011	9-0-1	Fernandez
33	Walmart Pharmacy #10-4279	Р	ABO	2019-04788	10-0-0	-
34	Tony Brown	R	ABO	2019-00513	8-0-2	Henke, Guerrero
35	Alexandra Hoang Mai Thi Cao	R	ABO	2019-05426	9-0-1	Lewis
36	Crosby Pharmacy and Wellness	Р	ABO	2020-02957	8-0-2	Lewis, Fernandez
37	CVS/pharmacy #5380	Р	ABO	2020-00316	8-0-2	Lewis, Tijerina
38	CVS/Pharmacy #7464	Р	ABO	2019-04590	8-0-2	Thornsburg, Tijerina
39	Andre Duruewuru	R	ABO	2019-05364	9-0-1	Lewis
40	Mary Elizabeth Dyer Even	R	ABO	2020-00084	9-0-1	Lewis
41	Excel Pharmacy, Inc.	Р	ABO	2019-01962	8-0-2	Henke, Guerrero
42	Victoria Adanna Metu	R	ABO	2019-03998	8-0-2	Henke, Guerrero

^{*}Technician or Technician Trainee (T), Pharmacist (R), and Pharmacy (P)
**Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

No.	Name	T, R, or P*	ABO, DBO, or RP**	Order # or Plan #	Board Vote (Yes-No- Recuse)	Recused Board Members
43	Omotayo Odusola	R	ABO	2019-04515	9-0-1	Lewis
44	Walgreens #03885	Р	ABO	2019-05285	7-0-3	Henke, Guerrero, Fernandez
45	Walgreens #4747	Р	ABO	2019-03064	7-0-3	Henke, Guerrero, Fernandez
46	Confidential	Р	ABO	2019-05832	9-0-1	Lewis
47	Confidential	Р	ABO	2020-01103	9-0-1	Thornsburg
48	Confidential	Р	ABO	2020-01594	8-0-2	Henke, Guerrero
49	Confidential	Р	ABO	2020-02721	9-0-1	Lewis
50	Confidential	Р	ABO	2020-01766	9-0-1	Lewis
51	Sheree Lanette Booker	Р	RP	2020-00003	10-0-0	-
52	Tiet Isabell Dang	Р	RP	2020-01610	10-0-0	-
53	Stanley U. Nwokoro	Р	RP	2020-00202	8-0-2	Henke, Guerrero
54	Morolake M. Olaleye	Р	RP	2019-04990	8-0-2	Lewis, Henke
55	Arnold Ray Yosten	Р	RP	2019-03884	8-0-2	Lewis, Fernandez

^{*}Technician or Technician Trainee (T), Pharmacist (R) and Pharmacy (P)
**Agreed Board Order (ABO), Default Board Order (DBO), and Remedial Plan (RP)

H. <u>Miscellaneous</u>

- Items to be Placed on Agenda for August 4, 2020 Board Meeting
 - Amendments Concerning Technician and Intern Duties and Ratios
- Discussion of and Possible Action on Upcoming Meetings

Ms. Benz reminded Board Members about upcoming informal conferences and informed them that Board staff would coordinate their Board member attendance at those informal conferences.

In response to a question from Mr. Miller regarding possible continuation of virtual meetings as a cost-saving measure, Ms. Benz explained that the Open Meetings Act requires the Board meetings to be held in-person and that those requirements were currently waived by the Governor. For the informal conferences, Ms. Arnold explained that virtual meetings could be considered and evaluated going forward.

Mr. Guerrero made a motion to adjourn the meeting. The motion was seconded by Mr. Tisch.

President Spier adjourned the meeting at 10:50 a.m.

APPROVED:

Julie Spier, R.Ph. President

Allison Vordenbaumen Benz, R.Ph., M.S. Executive Director/Secretary

August 4, 2020